Treatment with sildenafil and satisfaction with life in depressive patients with erectile dysfunction
Abstract
INTRODUCTION: To evaluate the effectiveness of Sildenafil in the treatment of erectile dysfunction (ED) in patients with depression; and the satisfaction with differents aspects of life.
METHODS: A multicenter, observational, prospective and non-comparative study conducted in primary care units. Effectiveness was measured by the questionnarie International Index of Erectile Function (IIEF), satisfaction with life by the Life Satisfaction Check-List (LSCL), and partner's satisfaction by Satisfaction with treatment of erectile dysfunction (EDITS). The study enrolled 330 patients with ED and Depression, treated with 50 mg (adjusted to 25/100 mg according to response) of Sildenafil for at least 10 weeks.
RESULTS: The erections improved for the 84.2%. At the initial visit a 58.2% had a severe dysfunction, and at the post-treatment visit for the 41.2% of the sample, the dysfunction was light. The most important increase in the LSCL was sexual activity and partner relationship.
CONCLUSIONS: Significant increases were observed in the LSCL was sexual activity and partner relationship.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 330 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.